Potential cost savings associated with dose rounding antineoplastic monoclonal agents

Conclusion Consultation with key physicians regarding the proposed percent reduction resulted in a 10% dose reduction for all cases when utilizing these three agents. Implementation of a dose rounding protocol for bevacizumab, trastuzumab, and cetuximab represents a potentially substantial cost savings at this institution.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research